Quadrivalent HPV vaccine in HIV-positive and HIV-negative men who have sex with men
Sorry, this learning module is not available for mobile devices.
Stephen Goldstone, MD, FACS
Assistant Clinical Professor of Surgery
Mount Sinai School of Medicine
Presentation Date: 5/18/2010
Release Date: 5/18/2010
- Understand the efficacy of quadrivalent HPV vaccine in preventing anal intraepithelial neoplasia in men who have sex with men.
- Understand the efficacy of quadrivalent HPV vaccine at preventing anal HPV infection in men who have sex with men.
- Discuss the safety profile of quadrivalent HPV vaccine in HIV-positive men.
Stephen Goldstone, MD, FACS is an Assistant Clinical Professor of Surgery at the Mount Sinai School of Medicine and has a surgical practice in New York City. He has developed a surgical technique to treat anal HPV dysplasia and is a member of the AIDS Malignancy Consortium. Dr. Goldstone is an expert on gay men's health, and has done extensive research on human papillomavirus (HPV), including prevention and treatment procedures for HPV.
PRN Learning Modules